inactivated split-virus influenza vaccine — Competitive Intelligence Brief

inactivated split-virus influenza vaccine (inactivated split-virus influenza vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated influenza vaccine. Area: Immunology.

marketed inactivated influenza vaccine Immunology Biologic

Target snapshot

inactivated split-virus influenza vaccine (inactivated split-virus influenza vaccine) — The Cleveland Clinic. This vaccine stimulates the immune system to recognize and respond to inactivated influenza virus particles, providing protection against seasonal influenza infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
inactivated split-virus influenza vaccine TARGET	inactivated split-virus influenza vaccine	The Cleveland Clinic	marketed	inactivated influenza vaccine
High-Dose Quadrivalent Influenza Vaccine	High-Dose Quadrivalent Influenza Vaccine	Tor Biering-Sørensen	marketed	Inactivated influenza vaccine
Standard Dose Quadrivalent Influenza Vaccine	Standard Dose Quadrivalent Influenza Vaccine	Hospital Israelita Albert Einstein	marketed	Inactivated influenza vaccine
FluarixTM	FluarixTM	GlaxoSmithKline	marketed	inactivated influenza vaccine
TIV	TIV	Folia Biotech Inc.	marketed	Inactivated influenza vaccine
Trivalent Influenza Vaccine	Trivalent Influenza Vaccine	MedImmune LLC	marketed	Inactivated influenza vaccine
Fluad Vaccine	Fluad Vaccine	David H. Canaday	marketed	Inactivated influenza vaccine with adjuvant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated influenza vaccine class)

1. Seqirus · 3 drugs in this class
2. Center for Disease Prevention and Control of Beijing Military Region · 2 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
4. Sinovac Biotech Co., Ltd · 2 drugs in this class
5. La Jolla Institute for Immunology · 1 drug in this class
6. Mount Sinai Hospital, Canada · 1 drug in this class
7. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
8. University of Sao Paulo · 1 drug in this class
9. GlaxoSmithKline · 1 drug in this class
10. University of Witwatersrand, South Africa · 1 drug in this class